Sanofi

We have completed the acquisition of Vigil Neuroscience, strengthening our early-stage pipeline in neurology and our research in various neurodegenerative diseases.   Read our press release: https://xmrrwallet.com/cmx.plnkd.in/efVY5xxZ

For some, it’s the spark of connection — spaces where ideas flow freely across teams and borders. For others, it’s calm — green spaces, fresh air, and healthy choices that create room to breathe and think big. And for many, it’s progress — with smart tools and technology that support their best work every day. Our workplace experience is thoughtfully designed, backed by research, and built for real people — like you. Because how you feel at work matters. That’s the #SanofiFeeling. Find yours. Explore your next career with us: http://xmrrwallet.com/cmx.pspkl.io/6049Ayqtt

Our CEO, Paul Hudson, shares his perspective on Q2 2025 — a quarter of continued progress across our pipeline, with key approvals and milestones achieved. Explore our second quarter results: https://xmrrwallet.com/cmx.plnkd.in/gQkmTpM5

Our second quarter 2025 results are now available. Read the press release: https://xmrrwallet.com/cmx.plnkd.in/gQkmTpM5   #SanofiResults

The FDA has granted Orphan Drug Designation to our investigational IgG1-based, GPRC5D-targeting antibody treatment for patients with relapsed or refractory #MultipleMyeloma (MM). This designation underscores our ongoing commitment to advancing new potential treatment options and addressing critical gaps in MM care. Read our press release: http://xmrrwallet.com/cmx.pspkl.io/6043AyBFR

One of the greatest unmet needs in #MultipleSclerosis (MS) is finding better ways to measure and treat disability progression. Scientific approaches need to evolve to address the challenges that have a significant impact on the daily life of those living with MS. Sanofi’s Luis Felipe O. discusses new ways to define disability in MS. Learn more ⤵️ http://xmrrwallet.com/cmx.pspkl.io/6045AHMjS

The European Commission has approved our combination therapy for the treatment of transplant-eligible newly diagnosed #MultipleMyeloma (MM) in the EU. The approval marks the fourth indication for our therapy in the EU, reinforcing our ambition to address critical unmet needs in MM care. http://xmrrwallet.com/cmx.pspkl.io/6043AH8cb

Imagine a future where lifelong medications become a one-time shot or diseases can be controlled by switching a therapy on and off. Our genomic medicine team has that world in our sights. Read more from Global Head of Genomic Medicine Christian Mueller on how we are building on gene therapy breakthroughs—once reserved for rare, monogenic disorders—to tackle more common immune-mediated diseases, with the goal of delivering more life-changing therapies to more people around the world. Learn more: http://xmrrwallet.com/cmx.pspkl.io/6044AGQcI #WeNeverSettle #DrugDiscovery #GeneTherapy

We are pleased to announce we’ve entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately held biotechnology company headquartered in London, UK. The acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), both respiratory viruses, and expands the capabilities in vaccine design and development with Vicebio’s ‘Molecular Clamp’ technology.      Read more in our press release: https://xmrrwallet.com/cmx.plnkd.in/d6N8Uirf  

We have completed the acquisition of Blueprint Medicines, expanding our portfolio in rare immunological disease, and adding early-stage pipeline in immunology. Read our press release: https://xmrrwallet.com/cmx.plnkd.in/eihvzCva